36 results about "Hepatitis B Antigens" patented technology

The present invention relates to a method for the production of a hepatitis B antigen suitable for use in a vaccine, the method comprising purification of the antigen in the presence of cysteine, to vaccines comprising such antigens.

Disclosed is a recombinant plasmid for expressing hepatitis B viral antigens in vivo, comprising an adeno-associated virus (AVV) vector and a replication-competent hepatitis B virus genome fragment. Mice hydrodynamically injected with the recombinant plasmid of the present invention show persistent expression of hepatitis B viral antigens for more than 6 months in the hepatocytes, thus a immuno-competent mouse model for persistent expression of hepatitis B antigens and also for human chronic hepatitis B virus infection is established, which can be applied in evaluation and elucidation of mechanism of chronic hepatitis and anti-viral drug discovery research.

The invention relates to a specific adsorbing material for removing hepatitis B virus protein in blood plasma, and a preparation method of the adsorbing material, and discloses a high polymer material which is prepared by coupling sepharose gel with gene-modified sodion taurocholic acid cotransporting polypeptide. The preparation method of the material comprises the steps of reacting the sepharose gel, which is taken as a carrier matrix, with a bi-glycidyl ether coupling reagent to obtain an active carrier, and subsequently, conducting coupling reaction on the active carrier with the sodion taurocholic acid cotransporting polypeptide which is fused with polypeptide tags. The synthesis method of the material is simple and convenient, the process route is short and the preparation is safe; and the material has the characteristics of strong specificity, high adsorption rate to the hepatitis B virus protein, good regenerability, harmlessness and no heat source reaction, and can be applied to clinical adsorption treatment to eliminate the hepatitis B virus protein in blood plasma in a specificity mode.

A drug for treating hepatitis B is characterized by being made from the mixture of bupleurum, gardenia, radix scutellariae, isatis root, salvia miltiorrhiza, herba artemisiae capillaris, rhubarb, rhizoma coptidis, cyperus rotundus, desmodium, rhizoma sparganii, endothelium corneum gigeriae galli, Chinese angelica, dried rhizome of rehmannia, radix aucklandiae, dried tangerine peel, sealwort, malt,hawthorn, medicated leaven, semen plantaginis, poria, turtle shell, date and gentian. The drug has simple process, the effects of adjusting immunologic function, inducing the occurrence of interferon, inhibiting and eliminating hepatitis B virus, promoting hepatocyte repair, improving liver microcirculation and promoting the reliable treating effect of hepatitis B antigen negative conversion, short treating period, fast effect, no relapse after cure and low cost. The drug is handed down from the ancestor over 200 years before and cures tens of thousands of patients with the effective rate upto 100 percent.

Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and / or pre-S2 region of the HBV envelope protein (HBVpreS1 / S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof.

Disclosed herein are DNA-based vaccines against amyloid β peptide for use in treating and alleviating Alzheimer's Disease and related conditions. A DNA construct comprising DNA encoding one or more amyloid β peptides, such as amino acids 1-11 of Aβ, and DNA encoding a hepatitis B antigens, is administered with an adjuvant or by electroporation. The vaccine can also be formulated using a fusion protein expressed by the disclosed DNA, in combination with an adjuvant.

The invention relates to the technical field of medicine and provides a hepatitis B virus (HBV)-infected mouse model construction method. According to the method, a polymerase chain reaction (PCR) is adopted to amplify an HBV single-copy linear genome, a PCR product transfects Huh7 cells, HepG2 cells and 293T cells, and hepatitis b surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in supernatant of culture cells are detected through an enzyme-linked immunosorbent assay (ELISA); the PCR product is injected to a C57BL / 6J mouse through a tail vein high-pressure hydrodynamic method, so that hepatitis b core antigen (HBcAG) in mouse liver tissue is detected in an immunohistochemistry mode, and the HBsAg and the HBeAG in serum of the mouse are detected in an ELISA mode. By means of the method, a novel HBV-infected mouse model is constructed, the model is simple in preparation method, and the HBC genome similar to the HBV cccDNA exists in the liver tissue. A novel tool is provided for research on an HBV cccDNA degradation mechanism, medicine removal, HBV biological characteristics in a serum sample of a hepatitis B patient and the like.

A thermosensitive hepatitis B vaccine is provided. The thermosensitive hepatitis B vaccine includes an aqueous phase solution comprising a biodegradable thermosensitive hydrogel copolymer; a surface antigen of hepatitis B virus (HBsAg); and a bioactive substance. The thermosensitive hepatitis B vaccine of the disclosure is particularly suitable for being applied in the patients, which are low responsive or non-responsive to conventional hepatitis B vaccine, for enhancing the induction of cell-mediated immune responses and overcoming the HBsAg non-responsiveness.